ReviewIndian journal of ophthalmology2026
The expanding horizon: Role of widefield imaging in uveitis.
Review in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional retinal imaging has historically been limited to the posterior pole, capturing only 30-50° field-of-view. The advent of widefield (WF) and ultra-widefield (UWF) imaging (WFI) technology has transformed this landscape, enabling visualization of up to 200° of retina in a single capture. This expanded field-of-view has revealed changes to help document peripheral retinal pathology like vascular leakage, areas of capillary nonperfusion, and early neovascularization, which was previously invisible to standard imaging, fundamentally changing how we stage disease, assess prognosis, and guide treatment decisions. WFI detects subclinical posterior involvement in a substantial proportion of patients initially classified as having anterior uveitis alone, necessitating diagnostic reclassification and treatment escalation in many cases. Beyond improved visualization, WFI has enabled objective quantification of disease burden through metrics such as leakage index and ischemic index. These continuous numerical biomarkers have largely replaced subjective clinical grading, providing standardized endpoints suitable for clinical trials and precision medicine applications. Recent advances in WF optical coherence tomography (OCT) and OCT angiography (OCTA) reveal layer-specific microvascular patterns and quantifiable perfusion deficits, offering unprecedented insight into disease mechanisms. Serial WF examinations document treatment response objectively, allowing clinicians to recognize therapeutic efficacy or failure earlier than subjective clinical assessment alone permits. Integration of quantitative WF metrics with artificial intelligence shows promise for automated objective analysis and prognostic modeling. This narrative review synthesizes the evidence supporting WFI across diagnostic applications, biomarker quantification, treatment guidance, complication detection, and treatment monitoring in uveitis. We examine practical implementation strategies, standardization efforts, and emerging technologies poised to advance the field further.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.